Skip to content

Accuracy of Magnetically Maneuvered Capsule Endoscopy for Detection of EGV in Patients With Cirrhosis

Accuracy of Magnetically Maneuvered Capsule Endoscopy for Detection of Esophagogastric Varices in Patients With Cirrhosis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03748563
Enrollment
607
Registered
2018-11-21
Start date
2021-01-07
Completion date
2023-03-06
Last updated
2023-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Varices, Gastric Varix, Liver Cirrhosis, Portal Hypertension

Keywords

Capsule Endoscopy, Liver Cirrhosis, Esophageal Varices, Gastric Varices, Portal hypertensive gastropathy, Portal hypertensive enteropathy

Brief summary

This is a diagnostic accuracy study. Eligible individuals will be enrolled and asked to undergo ds-MCE and EGD examinations. EGD is the reference standard against which ds-MCE is compared, and it will be performed within 48 hours after ds-MCE examination. The primary outcome is the sensitivity and specificity of ds-MCE in identifying the presence of esophagogastric (EGV) in patients with cirrhosis, using detection by EGD as the reference. The diagnostic accuracy of ds-MCE in detection of high-risk EV, high-risk EGV, EV, large EV, red signs of EV, GV, cardiofundal GV and PHG compared with the EGD will also be assessed. The incidence of PHE in small bowel under ds-MCE, the examination time of ds-MCE and EGD procedures, patient satisfaction assessment and safety evaluation will also be evaluated.

Detailed description

Cirrhosis is the major cause of liver disease-related morbidity and mortality worldwide. Portal hypertension (PH) is the hemodynamic abnormality in patients with cirrhosis, which is associated with various pathological changes throughout the entire gastrointestinal tract, manifesting as esophagogastric varices (EGV), portal hypertensive gastropathy (PHG), and portal hypertensive enteropathy (PHE). Baveno consensus and other practice guidelines recommended that patients with cirrhosis undergo endoscopic screening for EGV at the time of diagnosis and undergo periodic surveillance endoscopy throughout the whole course of cirrhosis. Esophagogastroduodenoscopy (EGD) is recognized as the gold standard for detection and follow-up of EGV in cirrhotic patients, allowing for direct mucosal visualization and therapeutic intervention. EGD is however an invasive procedure and there is potential for procedure-related complications, such as perforation and bleeding. Besides, conscious sedation is always required, leading to increased cost, risk, and inconvenience for the patients.These factors lead to a decrease of patient compliance as well as the effectiveness of the screening program. The capsule endoscopy (CE) system provides a noninvasive and relatively comfortable approach to visualize the GI tract, and the development of esophageal capsule endoscopy (ECE) makes it possible to capture clear images of esophagus without the need of sedation. However, the accuracy of ECE is not currently sufficient to replace EGD for the detection and grading for the esophageal varices. Besides, previous studies presented that the sensitivity of ECE for detecting gastric varices (GVs) and PHG varies from 3% to 69%, which denoted ECE was far from a suitable alternative for diagnosing gastric lesions. To overcome these limitations, a new technique, so-called detachable string magnetically maneuvered capsule endoscopy (ds-MCE) was developed. The ds-MCE system consists of two parts: the magnetically maneuvered capsule endoscopy (MCE) system and a transparent latex sleeve with a hollow string. One end of the hollow string is a transparent thin latex sleeve that can be wrapped on the surface of the capsule, and the other end of the string is connected to the syringe. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. In this case, investigator can examine the entire esophageal mucosa several times under real time views. The capsule then can be detached from the string system through injecting air into the hollow string with the syringe after completing the examination of esophagus. The magnetic capsule in the stomach can be accurately controlled through multidimensional rotation and adaptive matching of an external C-arm robot. Previous studies have demonstrated that the diagnostic accuracy of MCE for detecting gastric focal lesions is comparable with that of conventional EGD. Two previously studies of ds-MCE confirmed it was a feasible, safe and well-tolerated method for completely viewing esophagus and stomach, without the need for sedation. Besides, the 8-10h battery life of the ds-MCE enables complete examination of the small bowel, which enables to provide a more comprehensive evaluation of gastrointestinal changes. Considering all these backgrounds, in the current prospective study, the primary aim is to assess the diagnostic performance of the ds-MCE in identifying the presence of EGV in cirrhotic patients, using EGD as the reference standard. The diagnostic accuracy of ds-MCE in detection of high-risk EV, high-risk EGV, EV, large EV, red signs of EV, GV, cardiofundal GV and PHG compared with the EGD will also be assessed. The incidence of PHE in small bowel under ds-MCE, the examination time of ds-MCE and EGD procedures, patient satisfaction assessment and safety evaluation will also be evaluated.

Interventions

DIAGNOSTIC_TESTds-MCE and EGD

Procedure of ds-MCE: The ds-MCE system mainly consists of two parts: the NaviCam magnetically maneuvered capsule endoscopy system and the detachable string part. The capsule, which is partially enclosed within the sleeve, can be actively moved in the esophagus through the control of string. Investigator can examine the entire esophagus several times under real time views. After completing the esophageal examination, the capsule could be detached from the string through injecting air into the hollow string with the syringe. Then, the examination of stomach under magnetic control and small bowel under the natural action of gastrointestinal peristalsis follows. Procedure of EGD: The esophagogastroduodenoscopy (EGD) will be performed using conventional upper gastrointestinal video endoscopy, according to the standard procedure at individual centers. EGD will be performed within 48 hours after ds-MCE procedure and usually during the same endoscopic session.

Sponsors

Ruijin Hospital
CollaboratorOTHER
Shanghai Tongji Hospital, Tongji University School of Medicine
CollaboratorOTHER
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
CollaboratorOTHER
Shanghai East Hospital of Tongji University
CollaboratorOTHER
Yangpu District Central Hospital Affiliated to Tongji University
CollaboratorOTHER
Zhujiang Hospital
CollaboratorOTHER
Qilu Hospital of Shandong University
CollaboratorOTHER
The Third Xiangya Hospital of Central South University
CollaboratorOTHER
First Affiliated Hospital Xi'an Jiaotong University
CollaboratorOTHER
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
CollaboratorOTHER
The Fifth Affiliated Hospital of Zunyi Medical College
CollaboratorOTHER
The First Affiliated Hospital of Zhejiang Chinese Medical University
CollaboratorOTHER
Shanghai Pudong New Area Gongli Hospital
CollaboratorOTHER
Changhai Hospital
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Intervention model description

Diagnostic accuracy study

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Gender is not limited. 2. Patients aged 18 years or older. 3. Both inpatients and outpatients. 4. Clinically evident or biopsy-proven liver cirrhosis. 5. Able to provide informed consent.

Exclusion criteria

1. Patients aged less than 18 years. 2. Patients with Zenker's diverticulum. 3. Patients with active gastrointestinal bleeding. 4. Patients who have participated in or are participating in other clinical trials. 5. Pregnancy or suspected pregnancy. 6. Suspected or known intestinal stenosis or other known risk factors for capsule retention. 7. Pacemaker or other implanted electromedical devices which could interfere with magnetic resonance. 8. Patients with dysphagia. 9. Life-threatening conditions. 10. Patients plan to undergo magnetic resonance imaging examination before excretion of the MCE. 11. Patients who refuse to give informed consent. 12. Patients with any condition that precludes compliance with the study.

Design outcomes

Primary

MeasureTime frameDescription
the diagnostic accuracy of the ds-MCE in identifying the presence of esophagogastric varices (EGV)2 weeksthe sensitivity and specificity of ds-MCE in identifying EGV in patients with cirrhosis, using the detection by EGD as the reference.

Secondary

MeasureTime frameDescription
the diagnostic accuracy of the ds-MCE in identifying the red sign of EV2 weeksThe sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in identifying the red sign of EV, using the detection by EGD as the reference.
the diagnostic accuracy of the ds-MCE in differentiating large esophageal varices2 weeksThe sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in detection of large EV, using the detection by EGD as the reference.
the optimal esophageal luminal circumference percentage threshold under ds-MCE for distinguishing large EV2 weeksTo investigate the optimal threshold of the proportion of ds-MCE esophageal luminal circumference occupied by the largest esophageal varix present in differentiating large EV from small or no EV, using the detection by EGD as the reference.
the diagnostic accuracy of the ds-MCE in differentiating high-risk esophageal varices2 weeksThe sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in detection of high-risk EV, using the detection by EGD as the reference.
the diagnostic accuracy of the ds-MCE in detection of high-risk EGV2 weeksThe sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in detection of high-risk EGV, using the detection by EGD as the reference.
the diagnostic accuracy of the ds-MCE in detecting gastric varices (GV)2 weeksThe sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in detection of GV, using the detection by EGD as the reference.
the diagnostic accuracy of the ds-MCE in identifying the presence of esophageal varices (EV)2 weeksThe sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in detection of EV, using the detection by EGD as the reference.
the diagnostic accuracy of the ds-MCE in identifying portal hypertensive gastropathy2 weeksThe sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in detection of portal hypertensive gastropathy (PHG), using the detection by EGD as the reference.
the incidence of portal hypertensive enteropathy (PHE) under ds-MCE2 weeksEndoscopic findings of PHE include mucosal inflammatory-like abnormalities, vascular lesions and spontaneous bleeding.
the examination time of ds-MCE and EGD2 weeksExamination time of ds-MCE include esophageal transit time (ETT), gastric examination time (GET), gastric transit time (GTT), small bowel transit time (SBTT), and total running time (TRT). Examination time of EGD is the time from the endoscope entering to exiting from the esophagus.
patient satisfaction evaluation of the ds-MCE and EGD2 weeksPatient satisfaction score of ds-MCE and EGD procedures.
Safety evaluation2 weeksAll adverse events occurring during the study will be recorded.
the diagnostic accuracy of the ds-MCE in detecting cardiofundal gastric varices2 weeksThe sensitivity, specificity, PPV, NPV and overall diagnostic accuracy of ds-MCE in detection of cardiofundal GV, using the detection by EGD as the reference.

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 24, 2026